HTG Molecular Diagnostics and Instituto Valenciano de Oncología Initiate Breast Cancer Recurrence Risk Collaboration

TUCSON, Ariz., April 24, 2017 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, announced that it has entered into a research collaboration agreement with Instituto Valenciano de Oncología (IVO).  The initial project, utilizing the HTG EdgeSeq Oncology Biomarker Panel, will focus on the development and validation of a breast cancer recurrence risk score, based on genes that are differentially expressed between patients with low and high risk of recurrence.

“The goal of this research collaboration is to develop a breast cancer recurrence score, based on HTG’s technology, that is capable of using a single, formalin-fixed, paraffin-embedded (FFPE) tissue section that can be deployable for use by IVO and its affiliates for testing of breast cancer patients in Spain,” said Dr. Jose Antonio Lopez-Guerrero, Head of the Laboratory of Molecular Biology at IVO. IVO, located in Valencia, Spain, is a private, non-profit organization whose resources are used in the fight against cancer including prevention, diagnosis, treatment, research, and teaching.

“While other breast cancer recurrence risk scores are available on market, we believe this effort could result in a more cost-effective, decentralized laboratory solution that may allow patients to more quickly make informed decisions regarding their treatments,” explained TJ Johnson, President and Chief Executive Officer of HTG.  “We believe our HTG EdgeSeq chemistry is well suited for the initial project because it will allow IVO to develop their training set using a single, FFPE tissue section from each previously assessed case.”

About HTG:

Headquartered in Tucson, Arizona, the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG’s original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at

Safe Harbor Statement:

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the anticipated benefits or results of our agreement with Instituto Valenciano de Oncología, the capabilities of our technology, and our abilities to successfully develop diagnostic products with our research partners or otherwise and provide more cost-effective and decentralized solutions for patient care. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with the process of developing and commercializing diagnostic products, our ability to achieve and sustain sufficient market acceptance, and the capabilities of our product and service solutions to keep pace with rapidly changing technology and customer requirements. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10-K for the Year ended December 31, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Contact:

Westwicke Partners
Jamar Ismail
Phone: 415-513-1282

TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130